Skip to main content
Top

17-06-2024 | Dementia | Original Communication

Exploring the impact of 40 Hz multi-luminaire light exposure in Alzheimer's dementia: insights from a convenient sampling, non-randomized case–control study

Authors: Kuan-Ying Li, Ching-Fang Chien, Ling-Chun Huang, Kelly Lim, Yuan-Han Yang

Published in: Journal of Neurology

Login to get access

Abstract

Background

Recent studies propose 40 Hz neural activity induction as a promising approach for managing Alzheimer's dementia (AD). However, traditional flickering light is suboptimal in addressing cognitive and neuropsychiatric symptoms (NPS) of AD. This study aims to investigate the clinical efficacy of a novel multi-luminaire lighting technology, with reduced perceptible flickering, for treating AD NPS.

Methods

This study is a prospective, convenient sampling, non-randomized case–control investigation involving seventy-eight clinically diagnosed AD patients from 7 daycare centers. Thirty-five were exposed to 40 Hz light through Delta M + BrainCare Light (M +), 4 h daily, 5 days/week, for 12 weeks. The other 43 patients served as controls. Sum of boxes of the Clinical Dementia Rating (CDR-SB) scale, Neuropsychiatric Inventory (NPI), and Zarit Burden Interview (ZBI) were assessed at baseline and the 13th week.

Results

At baseline, the cases had worse cognitive function, lower cognitive score (Mini-Mental State Examination, p = 0.04; Cognitive Abilities Screening Instrument, p = 0.04), and advanced caregiver burden with higher ZBI scores (p < 0.01) than the controls. After the intervention, the cases had significant improvements in NPS as assessed using the NPI (p = 0.02), especially depression and euphoria symptoms (p = 0.04 and < 0.01, respectively) and less caregiver burden (ZBI score, p < 0.01). In global function, the control group showed a significant decline in CDR-SB score (p < 0.01), while the cases did not.

Conclusions

Results suggest M + may slow global function decline, preserve cognitive function, improve NPS, and reduce caregiver burden in AD patients. Larger studies with biomarkers are needed to explore underlying mechanisms.
Literature
1.
go back to reference Gaugler J, James B, Johnson T, Reimer J, Solis M, Weuve J, Buckley RF, Hohman TJ (2022) 2022 Alzheimer’s disease facts and figures. Alzheimers & Dementia 18:700–789CrossRef Gaugler J, James B, Johnson T, Reimer J, Solis M, Weuve J, Buckley RF, Hohman TJ (2022) 2022 Alzheimer’s disease facts and figures. Alzheimers & Dementia 18:700–789CrossRef
2.
go back to reference Qiu C, Kivipelto M, Von Strauss E (2009) Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11:111–128PubMedPubMedCentralCrossRef Qiu C, Kivipelto M, Von Strauss E (2009) Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11:111–128PubMedPubMedCentralCrossRef
3.
go back to reference Perl DP (2010) Neuropathology of Alzheimer’s disease. Mount Sinai J Med 77:32–42CrossRef Perl DP (2010) Neuropathology of Alzheimer’s disease. Mount Sinai J Med 77:32–42CrossRef
5.
go back to reference Golde TE (2023) Disease-modifying therapies for Alzheimer’s disease: more questions than answers. Neurotherapeutics 19:209–227CrossRef Golde TE (2023) Disease-modifying therapies for Alzheimer’s disease: more questions than answers. Neurotherapeutics 19:209–227CrossRef
6.
go back to reference Olivares D, Deshpande KV, Shi Y, Lahiri KD, Greig HN, Rogers TJ, Huang X (2012) N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res 9:746–758PubMedPubMedCentralCrossRef Olivares D, Deshpande KV, Shi Y, Lahiri KD, Greig HN, Rogers TJ, Huang X (2012) N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res 9:746–758PubMedPubMedCentralCrossRef
7.
go back to reference Wu W, Ji Y, Wang Z, Wu X, Li J, Gu F, Chen Z, Wang Z (2023) The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res 28:544PubMedPubMedCentralCrossRef Wu W, Ji Y, Wang Z, Wu X, Li J, Gu F, Chen Z, Wang Z (2023) The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res 28:544PubMedPubMedCentralCrossRef
8.
go back to reference Hershey LA, Tarawneh R (2021) Clinical efficacy, drug safety, and surrogate endpoints: has aducanumab met all of its expectations? In: AAN Enterprises, pp 517–518 Hershey LA, Tarawneh R (2021) Clinical efficacy, drug safety, and surrogate endpoints: has aducanumab met all of its expectations? In: AAN Enterprises, pp 517–518
9.
go back to reference Withington CG, Turner RS (2022) Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer’s disease. Front Neurol 13:862369PubMedPubMedCentralCrossRef Withington CG, Turner RS (2022) Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer’s disease. Front Neurol 13:862369PubMedPubMedCentralCrossRef
10.
go back to reference Huang L-C, Yang Y-H (2022) The long-term effects of immersive virtual reality reminiscence in people with dementia: longitudinal observational study. JMIR Serious Games 10:e36720PubMedPubMedCentralCrossRef Huang L-C, Yang Y-H (2022) The long-term effects of immersive virtual reality reminiscence in people with dementia: longitudinal observational study. JMIR Serious Games 10:e36720PubMedPubMedCentralCrossRef
11.
go back to reference Zucchella C, Sinforiani E, Tamburin S, Federico A, Mantovani E, Bernini S, Casale R, Bartolo M (2018) The multidisciplinary approach to Alzheimer’s disease and dementia. A narrative review of non-pharmacological treatment. Front Neurol 9:1058PubMedPubMedCentralCrossRef Zucchella C, Sinforiani E, Tamburin S, Federico A, Mantovani E, Bernini S, Casale R, Bartolo M (2018) The multidisciplinary approach to Alzheimer’s disease and dementia. A narrative review of non-pharmacological treatment. Front Neurol 9:1058PubMedPubMedCentralCrossRef
12.
go back to reference Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C (2010) Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 30:161–178PubMedCrossRef Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C (2010) Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 30:161–178PubMedCrossRef
13.
go back to reference Wang L-Y, Pei J, Zhan Y-J, Cai Y-W (2020) Overview of meta-analyses of five non-pharmacological interventions for Alzheimer’s disease. Front Aging Neurosci 12:594432PubMedPubMedCentralCrossRef Wang L-Y, Pei J, Zhan Y-J, Cai Y-W (2020) Overview of meta-analyses of five non-pharmacological interventions for Alzheimer’s disease. Front Aging Neurosci 12:594432PubMedPubMedCentralCrossRef
15.
go back to reference Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149:708–721PubMedPubMedCentralCrossRef Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149:708–721PubMedPubMedCentralCrossRef
17.
go back to reference Stam CJ, van Walsum AMVC, Pijnenburg YA, Berendse HW, de Munck JC, Scheltens P, van Dijk BW (2002) Generalized synchronization of MEG recordings in Alzheimer’s disease: evidence for involvement of the gamma band. J Clin Neurophysiol 19:562–574PubMedCrossRef Stam CJ, van Walsum AMVC, Pijnenburg YA, Berendse HW, de Munck JC, Scheltens P, van Dijk BW (2002) Generalized synchronization of MEG recordings in Alzheimer’s disease: evidence for involvement of the gamma band. J Clin Neurophysiol 19:562–574PubMedCrossRef
18.
go back to reference König T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, Jelic V (2005) Decreased EEG synchronization in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 26:165–171CrossRef König T, Prichep L, Dierks T, Hubl D, Wahlund LO, John ER, Jelic V (2005) Decreased EEG synchronization in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 26:165–171CrossRef
19.
go back to reference McDermott B, Porter E, Hughes D, McGinley B, Lang M, O’Halloran M, Jones M (2018) Gamma band neural stimulation in humans and the promise of a new modality to prevent and treat Alzheimer’s disease. J Alzheimers Dis 65:363–392PubMedPubMedCentralCrossRef McDermott B, Porter E, Hughes D, McGinley B, Lang M, O’Halloran M, Jones M (2018) Gamma band neural stimulation in humans and the promise of a new modality to prevent and treat Alzheimer’s disease. J Alzheimers Dis 65:363–392PubMedPubMedCentralCrossRef
20.
go back to reference Adaikkan C, Tsai L-H (2020) Gamma entrainment: impact on neurocircuits, glia, and therapeutic opportunities. Trends Neurosci 43:24–41PubMedCrossRef Adaikkan C, Tsai L-H (2020) Gamma entrainment: impact on neurocircuits, glia, and therapeutic opportunities. Trends Neurosci 43:24–41PubMedCrossRef
21.
go back to reference Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F (2016) Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540:230–235PubMedPubMedCentralCrossRef Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F (2016) Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature 540:230–235PubMedPubMedCentralCrossRef
22.
go back to reference Adaikkan C, Middleton SJ, Marco A, Pao P-C, Mathys H, Kim DN-W, Gao F, Young JZ, Suk H-J, Boyden ES (2019) Gamma entrainment binds higher-order brain regions and offers neuroprotection. Neuron 102(929–943):e928 Adaikkan C, Middleton SJ, Marco A, Pao P-C, Mathys H, Kim DN-W, Gao F, Young JZ, Suk H-J, Boyden ES (2019) Gamma entrainment binds higher-order brain regions and offers neuroprotection. Neuron 102(929–943):e928
23.
go back to reference Martorell AJ, Paulson AL, Suk H-J, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN-W, Kritskiy O, Barker SJ (2019) Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell 177(256–271):e222 Martorell AJ, Paulson AL, Suk H-J, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN-W, Kritskiy O, Barker SJ (2019) Multi-sensory gamma stimulation ameliorates Alzheimer’s-associated pathology and improves cognition. Cell 177(256–271):e222
24.
go back to reference Cimenser A, Hempel E, Travers T, Strozewski N, Martin K, Malchano Z, Hajós M (2021) Sensory-evoked 40-Hz gamma oscillation improves sleep and daily living activities in Alzheimer’s disease patients. Front Syst Neurosci 15:746859PubMedPubMedCentralCrossRef Cimenser A, Hempel E, Travers T, Strozewski N, Martin K, Malchano Z, Hajós M (2021) Sensory-evoked 40-Hz gamma oscillation improves sleep and daily living activities in Alzheimer’s disease patients. Front Syst Neurosci 15:746859PubMedPubMedCentralCrossRef
25.
go back to reference Chan D, Suk H-J, Jackson BL, Milman NP, Stark D, Klerman EB, Kitchener E, Avalos VSF, de Weck G, Banerjee A (2022) Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies. PLoS ONE 17:e0278412PubMedPubMedCentralCrossRef Chan D, Suk H-J, Jackson BL, Milman NP, Stark D, Klerman EB, Kitchener E, Avalos VSF, de Weck G, Banerjee A (2022) Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies. PLoS ONE 17:e0278412PubMedPubMedCentralCrossRef
26.
go back to reference McNett SD, Vyshedskiy A, Savchenko A, Durakovic D, Heredia G, Cahn R, Kogan M (2023) A feasibility study of AlzLife 40 Hz sensory therapy in patients with MCI and early AD. In: Healthcare. MDPI, p 2040 McNett SD, Vyshedskiy A, Savchenko A, Durakovic D, Heredia G, Cahn R, Kogan M (2023) A feasibility study of AlzLife 40 Hz sensory therapy in patients with MCI and early AD. In: Healthcare. MDPI, p 2040
27.
go back to reference McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedCrossRef McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedCrossRef
28.
go back to reference Chang Y-P, Chien C-F, Huang L-C, Chuu C-P, Chang H-W, Hour T-C, Yang Y-H (2024) White light stimulation at gamma frequency to modify the Aβ42 and tau proteins in SH-SY5Y cells. Am J Alzheimer’s Dis Other Dement 39:15333175241236252CrossRef Chang Y-P, Chien C-F, Huang L-C, Chuu C-P, Chang H-W, Hour T-C, Yang Y-H (2024) White light stimulation at gamma frequency to modify the Aβ42 and tau proteins in SH-SY5Y cells. Am J Alzheimer’s Dis Other Dement 39:15333175241236252CrossRef
29.
go back to reference Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D (1994) The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6:45–58PubMedCrossRef Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D (1994) The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6:45–58PubMedCrossRef
30.
go back to reference Chiu E-C, Chien T-H, Lee Y-C (2021) Measurement equivalence between the original and estimated mini-mental state examination in people with dementia. Int J Environ Res Public Health 18:7616PubMedPubMedCentralCrossRef Chiu E-C, Chien T-H, Lee Y-C (2021) Measurement equivalence between the original and estimated mini-mental state examination in people with dementia. Int J Environ Res Public Health 18:7616PubMedPubMedCentralCrossRef
31.
go back to reference Morris JC (1993) The Clinical Dementia Rating (CDR) current version and scoring rules. Neurology 43:2412–2412-aPubMedCrossRef Morris JC (1993) The Clinical Dementia Rating (CDR) current version and scoring rules. Neurology 43:2412–2412-aPubMedCrossRef
32.
go back to reference Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12:233–239PubMedCrossRef Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, Lopez OL, DeKosky ST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12:233–239PubMedCrossRef
33.
go back to reference Zarit SH, Orr NK, Zarit JM (1985) The hidden victims of Alzheimer’s disease: Families under stress. NYU press Zarit SH, Orr NK, Zarit JM (1985) The hidden victims of Alzheimer’s disease: Families under stress. NYU press
34.
go back to reference Hébert R, Bravo G, Préville M (2000) Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging/La Revue canadienne du vieillissement 19:494–507CrossRef Hébert R, Bravo G, Préville M (2000) Reliability, validity and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can J Aging/La Revue canadienne du vieillissement 19:494–507CrossRef
35.
go back to reference Hedges LV, Olkin I (2014) Statistical methods for meta-analysis. Academic Press Hedges LV, Olkin I (2014) Statistical methods for meta-analysis. Academic Press
36.
go back to reference He Q, Colon-Motas KM, Pybus AF, Piendel L, Seppa JK, Walker ML, Manzanares CM, Qiu D, Miocinovic S, Wood LB (2021) A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer’s disease. Alzheimer’s Dementia Transl Res Clin Interv 7:e12178CrossRef He Q, Colon-Motas KM, Pybus AF, Piendel L, Seppa JK, Walker ML, Manzanares CM, Qiu D, Miocinovic S, Wood LB (2021) A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer’s disease. Alzheimer’s Dementia Transl Res Clin Interv 7:e12178CrossRef
37.
go back to reference Yang Y-H, Wu M-N, Chou P-S, Su H-C, Lin S-H, Sung P-S (2018) Longitudinal neuropsychological outcome in Taiwanese Alzheimer’s disease patients treated with medication. Curr Alzheimer Res 15:474–481PubMedCrossRef Yang Y-H, Wu M-N, Chou P-S, Su H-C, Lin S-H, Sung P-S (2018) Longitudinal neuropsychological outcome in Taiwanese Alzheimer’s disease patients treated with medication. Curr Alzheimer Res 15:474–481PubMedCrossRef
38.
go back to reference Da X, Hempel E, Ou Y, Rowe OE, Malchano Z, Hajós M, Kern R, Thomas Megerian J, Cimenser A (2024) Noninvasive gamma sensory stimulation may reduce white matter and myelin loss in Alzheimer’s disease. J Alzheimer's Dis 97:395–372 Da X, Hempel E, Ou Y, Rowe OE, Malchano Z, Hajós M, Kern R, Thomas Megerian J, Cimenser A (2024) Noninvasive gamma sensory stimulation may reduce white matter and myelin loss in Alzheimer’s disease. J Alzheimer's Dis 97:395–372
39.
go back to reference Sekulovski D, Poort S, Perz M, Waumans L (2020) Effects of long-term exposure to stroboscopic effect from moderate-level modulated light. Light Res Technol 52:775–789CrossRef Sekulovski D, Poort S, Perz M, Waumans L (2020) Effects of long-term exposure to stroboscopic effect from moderate-level modulated light. Light Res Technol 52:775–789CrossRef
40.
go back to reference Agger MP, Danielsen ER, Carstensen MS, Nguyen NM, Horning M, Henney MA, Jensen CBR, Baandrup AO, Kjaer TW, Madsen KH (2023) Safety, feasibility, and potential clinical efficacy of 40 hz invisible spectral flicker versus placebo in patients with mild-to-moderate Alzheimer’s disease: a randomized, placebo-controlled, double-blinded, pilot study. J Alzheimers Dis 92:653–665PubMedCrossRef Agger MP, Danielsen ER, Carstensen MS, Nguyen NM, Horning M, Henney MA, Jensen CBR, Baandrup AO, Kjaer TW, Madsen KH (2023) Safety, feasibility, and potential clinical efficacy of 40 hz invisible spectral flicker versus placebo in patients with mild-to-moderate Alzheimer’s disease: a randomized, placebo-controlled, double-blinded, pilot study. J Alzheimers Dis 92:653–665PubMedCrossRef
41.
go back to reference Hsieh SW, Huang LC, Hsieh TJ, Lin CF, Hsu CC, Yang YH (2021) Behavioral and psychological symptoms in institutional residents with dementia in Taiwan. Geriatr Gerontol Int 21:718–724PubMedCrossRef Hsieh SW, Huang LC, Hsieh TJ, Lin CF, Hsu CC, Yang YH (2021) Behavioral and psychological symptoms in institutional residents with dementia in Taiwan. Geriatr Gerontol Int 21:718–724PubMedCrossRef
42.
go back to reference Cheng S-T (2017) Dementia caregiver burden: a research update and critical analysis. Curr Psychiatry Rep 19:1–8CrossRef Cheng S-T (2017) Dementia caregiver burden: a research update and critical analysis. Curr Psychiatry Rep 19:1–8CrossRef
44.
go back to reference Du X, Wang S, Zhang X, Wan Y, Tao H, Xue R (2020) Gamma oscillations of cognitive dysfunction in chronic insomnia patients with anxiety and depression. Chin J Behav Med Brain Sci 12:523–528 Du X, Wang S, Zhang X, Wan Y, Tao H, Xue R (2020) Gamma oscillations of cognitive dysfunction in chronic insomnia patients with anxiety and depression. Chin J Behav Med Brain Sci 12:523–528
45.
go back to reference Li Q, Takeuchi Y, Wang J, Gellért L, Barcsai L, Pedraza LK, Nagy AJ, Kozák G, Nakai S, Kato S (2023) Reinstating olfactory bulb-derived limbic gamma oscillations alleviates depression-like behavioral deficits in rodents. Neuron 111(2065–2075):e2065CrossRef Li Q, Takeuchi Y, Wang J, Gellért L, Barcsai L, Pedraza LK, Nagy AJ, Kozák G, Nakai S, Kato S (2023) Reinstating olfactory bulb-derived limbic gamma oscillations alleviates depression-like behavioral deficits in rodents. Neuron 111(2065–2075):e2065CrossRef
46.
go back to reference Tai S-Y, Chen C-H, Chien C-Y, Yang Y-H (2017) Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study. BMC Neurol 17:1–6CrossRef Tai S-Y, Chen C-H, Chien C-Y, Yang Y-H (2017) Cilostazol as an add-on therapy for patients with Alzheimer’s disease in Taiwan: a case control study. BMC Neurol 17:1–6CrossRef
47.
go back to reference Li K-Y, Lin B-T, Hsu S-T, Chien C-F, Chang Y-P, Yang Y-H (2023) Quetiapine oral solution in Alzheimer’s disease: efficacy and dosage insights from a real-world retrospective study. J Alzheimer's Dis 97:805–811CrossRef Li K-Y, Lin B-T, Hsu S-T, Chien C-F, Chang Y-P, Yang Y-H (2023) Quetiapine oral solution in Alzheimer’s disease: efficacy and dosage insights from a real-world retrospective study. J Alzheimer's Dis 97:805–811CrossRef
Metadata
Title
Exploring the impact of 40 Hz multi-luminaire light exposure in Alzheimer's dementia: insights from a convenient sampling, non-randomized case–control study
Authors
Kuan-Ying Li
Ching-Fang Chien
Ling-Chun Huang
Kelly Lim
Yuan-Han Yang
Publication date
17-06-2024
Publisher
Springer Berlin Heidelberg
Keywords
Dementia
Dementia
Published in
Journal of Neurology
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-024-12486-y